Skip to main content
. 2016 Sep 6;7(42):68597–68613. doi: 10.18632/oncotarget.11860

Figure 3. Erlotinib treatment induces faster degradation of L858R and delE746-A750 EGFR proteins in NSCLC cells.

Figure 3

A. List of cell lines, respective mutations and their sensitivities to erlotinib are summarized. B. HCC827 (delE746-A750), NCI-H3255 (L858R) and NCI-H1975 (L858R/T790M) cells harboring the above mentioned EGFR mutations were either treated with DMSO or with 3 μM erlotinib for 12 h. Following treatment, cells were treated with 50 μg/ml of cycloheximide (CHX), and cell lysates were prepared at the indicated time points. Immunoblotting analyses were performed using the indicated antibodies. C. Band intensities (arbitrary units, a.u.) were measured using Image J software, and each graph represents mean ± SEM from three independent experiments for an individual cell line.